Gonadotropin-releasing hormone agonists in breast cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1589, 2007-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging gonadotropin-releasing hormone agonists

By Beyer Daniel Alexander Amari Feriel Thill Marc Schultze-Mosgau Askan Al-Hasani Safaa Diedrich Klaus Griesinger Georg

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 323-340

Informa Healthcare

Access to resources Recommend Favorite

Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

By Saylor Philip J.

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 255-261

Adis International

Access to resources Recommend Favorite

New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

By Schultze-Mosgau Askan Griesinger Georg Altgassen Christopher von Otte Soeren Hornung Daniela Diedrich Klaus

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 9, 2005-09 ,pp. : 1085-1097

Informa Healthcare

Access to resources Recommend Favorite

Gonadotropin-releasing hormone antagonists

By Herbst K.L.

Current Opinion in Pharmacology, Vol. 3, Iss. 6, 2003-12 ,pp. : 660-666

Elsevier

Access to resources Recommend Favorite

Gonadotropin-releasing hormone antagonists reviewed

Inpharma, Vol. 1, Iss. 1316, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite